A data-manipulation episode involving a drug that costs $2.1 million tests an executive who is trying to rebuild trust in the company
Novartis AG Chief Executive Vas Narasimhan has spent part of his 18 months at the helm of the drug giant cleaning up issues that emerged before his watch. Now, he is facing a storm of his own making.
Dr. Narasimhan said on a call with analysts earlier this month that the company kept a data-manipulation issue under wraps while the Food and Drug Administration completed its review of Novartis’s Zolgensma, the world’s most expensive drug. The Swiss company has said it wanted to finish its own review before alerting the FDA,...
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Cathay Pacific Airways CEO Rupert Hogg resigns as Chinese scrutiny mountsCathay Pacific Airways CEO Rupert Hogg resigned in a shock move on Fri...
Consulte Mais informação »
GE rebounds after CEO share purchases, Wall Street analysts come to company's defenseGE bounced back Friday after the CEO shored up confidence in buying a bulk of company shares, and analysts defended the industrial giant.
Consulte Mais informação »
Cathay CEO resigns amid Hong Kong protest blowback as more rallies plannedThe boss of Hong Kong carrier Cathay Pacific Airways quit on Friday, the highest...
Consulte Mais informação »
Cathay Pacific CEO resigns after Beijing pressureThe CEO of Cathay Pacific Airways, one of Hong Kong&39;s most prominent companies, resigned Friday following pressure by Beijing on the carrier over participation by some of its employees in anti-government protests. Rupert Hogg became the highest-profile corporate casualty of official Chinese pressure
Consulte Mais informação »
BMW's CEO urges staff to narrow sales gap with MercedesBMW's new chief executive urged employees to embrace change and to find inn...
Consulte Mais informação »